Virtual Reality Therapy for Mal de Débarquement Syndrome
Trial Summary
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
A case report showed that using a virtual reality environment to replicate a treatment involving head movements and visual stimuli led to complete symptom resolution in a patient with Mal de Débarquement Syndrome after just two sessions. Additionally, virtual reality-assisted therapy has been shown to improve treatment outcomes for vestibular disorders compared to conventional therapy.
12345Virtual reality therapy has been used safely in treating various vestibular conditions, such as peripheral vestibular dysfunction and Mal de Débarquement Syndrome, with no reported adverse effects in the studies reviewed.
12367The DevRobust Treatment is unique because it uses virtual reality to replicate a specific therapy that involves passive head movements while watching moving stripes, which helps readjust the vestibulo-ocular reflex (VOR) and alleviate symptoms. This approach is novel compared to traditional vestibular rehabilitation, which may not specifically target the maladaptation seen in Mal de Débarquement Syndrome.
12367Eligibility Criteria
This trial is for individuals with Mal de Débarquement Syndrome who feel better when in passive motion. It's not suitable for those with claustrophobia, certain neurological disorders like MS or epilepsy, abnormal inner ear function tests, injuries affecting mobility without support, prior VOR readaptation treatment, or high anxiety levels.Inclusion Criteria
Exclusion Criteria
Trial Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive VOR readaptation treatment with either full-field OKS or VR goggles for 1-2 hours a day over 5 days
Follow-up
Participants are monitored for safety and effectiveness after treatment, with assessments at baseline and 6 months
Extension
Participants may receive additional treatment focusing on VID or MS susceptibility if symptoms persist